Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR N826S
EGFR N826S - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/4496
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1188
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Erlotinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 19147750
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Erlotinib | Resitance or Non-Reponse | true |